Idorsia Ltd
SIX:IDIA

Watchlist Manager
Idorsia Ltd Logo
Idorsia Ltd
SIX:IDIA
Watchlist
Price: 0.6325 CHF -50.35% Market Closed
Market Cap: 114m CHF
Have any thoughts about
Idorsia Ltd?
Write Note

Idorsia Ltd
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Idorsia Ltd
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Idorsia Ltd
SIX:IDIA
Cash & Cash Equivalents
CHf145.1m
CAGR 3-Years
1%
CAGR 5-Years
-29%
CAGR 10-Years
N/A
AC Immune SA
NASDAQ:ACIU
Cash & Cash Equivalents
CHf32.4m
CAGR 3-Years
-30%
CAGR 5-Years
-31%
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Cash & Cash Equivalents
$225.7m
CAGR 3-Years
-39%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Molecular Partners AG
SIX:MOLN
Cash & Cash Equivalents
CHf65.7m
CAGR 3-Years
-20%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Cash & Cash Equivalents
CHf63m
CAGR 3-Years
-9%
CAGR 5-Years
-13%
CAGR 10-Years
-7%
Kuros Biosciences AG
SIX:KURN
Cash & Cash Equivalents
CHf13.7m
CAGR 3-Years
-20%
CAGR 5-Years
2%
CAGR 10-Years
N/A
No Stocks Found

Idorsia Ltd
Glance View

Market Cap
119.1m CHF
Industry
Biotechnology

Idorsia Ltd. operates as a biopharmaceutical firm which focuses on discovery, development and commercialization of innovative medicines for unmet medical needs. The company is headquartered in Allschwil, Basel-Landschaft. The company went IPO on 2017-06-16. The firm will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The firm's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.

IDIA Intrinsic Value
Not Available

See Also

What is Idorsia Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
145.1m CHF

Based on the financial report for Dec 31, 2023, Idorsia Ltd's Cash & Cash Equivalents amounts to 145.1m CHF.

What is Idorsia Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-29%

Over the last year, the Cash & Cash Equivalents growth was -1%. The average annual Cash & Cash Equivalents growth rates for Idorsia Ltd have been 1% over the past three years , -29% over the past five years .

Back to Top